Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Carrie M. Hersh, Richard A. Brook, Ian A. Beren, Nicholas J. Rohrbacker, Lori Lebson, Christian Henke & Amy L. Phillips. (2021) The implications of suboptimal year-1 outcomes with disease-modifying therapy in employees with multiple sclerosis. Journal of Medical Economics 24:1, pages 479-486.
Read now
Read now
Benjamin Greenberg, Steven Hall, Michael Grabner, Sanjeev Balu, Xian Zhang & Daniel Kantor. (2020) Multiple sclerosis relapse rates and healthcare costs of two versions of glatiramer acetate. Current Medical Research and Opinion 36:7, pages 1167-1175.
Read now
Read now
Matthew Putnam, Mollie Vanderkarr, Piyush Nandwani, Chantal E. Holy & Abhishek S. Chitnis. (2019) Surgical treatment, complications, and reimbursement among patients with clavicle fracture and acromioclavicular dislocations: a US retrospective claims database analysis. Journal of Medical Economics 22:9, pages 901-908.
Read now
Read now
Natalie C Edwards, Michael Munsell, Joseph Menzin & Amy L Phillips. (2018) Comorbidity in US patients with multiple sclerosis. Patient Related Outcome Measures 9, pages 97-102.
Read now
Read now
Frank A. Corvino, David Oliveri & Amy L. Phillips. (2017) The association of timing of disease-modifying drug initiation and relapse in patients with multiple sclerosis using electronic health records. Current Medical Research and Opinion 33:6, pages 1127-1132.
Read now
Read now
Xuehua Ke, Prakash Navaratnam, Rahul Sasane, Debra F. Eisenberg Lawrence, Howard S. Friedman, Bernard B. Tulsi & Timothy Vollmer. (2016) Determinants of high cost in multiple sclerosis patients: a claims and chart review study. Current Medical Research and Opinion 32:9, pages 1589-1597.
Read now
Read now
Hugh Tilson. (2015) The evidence for a changing real world of real world evidence. Current Medical Research and Opinion 31:5, pages 1027-1028.
Read now
Read now
Articles from other publishers (20)
Mackenzie Henderson, Daniel B. Horton, Vikram Bhise, Gian Pal, Greta Bushnell & Chintan V. Dave. (2023) Initiation Patterns of Disease-Modifying Therapies for Multiple Sclerosis Among US Adults and Children, 2001 Through 2020. JAMA Neurology 80:8, pages 860.
Crossref
Crossref
Simone Wolf, Abhishek S. Chitnis, Anandan Manoranjith, Mollie Vanderkarr, Javier Quintana Plaza, Laura V. Gador, Chantal E. Holy, Charisse Sparks & Simon M. Lambert. (2022) Surgical treatment, complications, reoperations, and healthcare costs among patients with clavicle fracture in England. BMC Musculoskeletal Disorders 23:1.
Crossref
Crossref
Tamás Biernacki, Dániel Sandi, Judit Füvesi, Zsanett Fricska-Nagy, Tamás Zsigmond Kincses, Péter Ács, Csilla Rózsa, Enikő Dobos, Botond Cseh, László Horváth, Zsuzsanna Nagy, Attila Csányi, Krisztina Kovács, Tünde Csépány, László Vécsei & Krisztina Bencsik. (2022) The safety and efficacy of fingolimod: Real-world data from a long-term, non-interventional study on the treatment of RRMS patients spanning up to 5 years from Hungary. PLOS ONE 17:4, pages e0267346.
Crossref
Crossref
Anthony T Reder, Nancy Arndt, Cortnee Roman, Caroline Geremakis, Jason P Mendoza, Ray Su, Charles Makin, Robin L Avila & Megan C Vignos. (2021) Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders 51, pages 102935.
Crossref
Crossref
Debra E. Irwin, Kim Kelly, Isabelle Winer, Til Stürmer & Robert Zura. (2021) Methodologies for Validation of Diagnoses in Real-World Data: BONES—A Case Study. Journal of Orthopaedic Trauma 35:1, pages S28-S32.
Crossref
Crossref
Ehab Hasan. 2021. Pragmatic Randomized Clinical Trials. Pragmatic Randomized Clinical Trials
443
454
.
Tjalf ZiemssenMichael LangBjörn TackenbergStephan SchmidtHolger AlbrechtLuisa KlotzJudith HaasChristoph LassekC. Anne-Marie CoutoJohn A. FindlayChristian Cornelissen. (2019) Real-world persistence and benefit–risk profile of fingolimod over 36 months in Germany. Neurology Neuroimmunology & Neuroinflammation 6:3.
Crossref
Crossref
Yizhou Ye, Sudhakar Manne & Dimitri Bennett. (2019) Identifying Patients With Inflammatory Bowel Diseases in an Administrative Health Claims Database: Do Algorithms Generate Similar Findings?. INQUIRY: The Journal of Health Care Organization, Provision, and Financing 56, pages 004695801988781.
Crossref
Crossref
Hoa Van Le, Chi Thi Le Truong, Aaron W.C. Kamauu, John Holmén, Christopher Fillmore, Monica G. Kobayashi, Canter Martin, Meritxell Sabidó & Schiffon L. Wong. (2019) Identifying Patients With Relapsing-Remitting Multiple Sclerosis Using Algorithms Applied to US Integrated Delivery Network Healthcare Data. Value in Health 22:1, pages 77-84.
Crossref
Crossref
Maria K. HoutchensNatalie C. EdwardsAmy L. Phillips. (2018) Relapses and disease-modifying drug treatment in pregnancy and live birth in US women with MS. Neurology 91:17.
Crossref
Crossref
James D Bowen, Chris M Kozma, Megan M Grosso & Amy L Phillips. (2018) A real-world comparison of relapse rates, healthcare costs and resource use among patients with multiple sclerosis newly initiating subcutaneous interferon beta-1a versus oral disease-modifying drugs. Multiple Sclerosis Journal - Experimental, Translational and Clinical 4:4, pages 205521731881903.
Crossref
Crossref
Jay Visaria, Nina Thomas, Tao Gu, Joseph Singer & Hiangkiat Tan. (2018) Understanding the Patient's Journey in the Diagnosis and Treatment of Multiple Sclerosis in Clinical Practice. Clinical Therapeutics 40:6, pages 926-939.
Crossref
Crossref
. 2018. Post-Authorization Safety Studies of Medicinal Products. Post-Authorization Safety Studies of Medicinal Products
49
103
.
Tjalf Ziemssen, Michael Lang, Björn Tackenberg, Stephan Schmidt, Holger Albrecht, Luisa Klotz, Judith Haas, Christoph Lassek, Jennie Medin & Christian Cornelissen. (2017) Clinical and Demographic Profile of Patients Receiving Fingolimod in Clinical Practice in Germany and the Benefit–Risk Profile of Fingolimod After 1 Year of Treatment: Initial Results From the Observational, Noninterventional Study PANGAEA. Neurotherapeutics 15:1, pages 190-199.
Crossref
Crossref
Michael Munsell, Molly Frean, Joseph Menzin & Amy L. Phillips. (2017) Development and validation of a claims-based measure as an indicator for disease status in patients with multiple sclerosis treated with disease-modifying drugs. BMC Neurology 17:1.
Crossref
Crossref
Gorana Capkun, Aoife Callan, Haijun Tian, Zhongyuan Wei, Changgeng Zhao, Neetu Agashivala & Victoria Barghout. (2017) Burden of illness and healthcare resource use in United States patients with sporadic inclusion body myositis. Muscle & Nerve 56:5, pages 861-867.
Crossref
Crossref
Stéphanie Foulon, Géric Maura, Marie Dalichampt, François Alla, Marc Debouverie, Thibault Moreau & Alain Weill. (2017) Prevalence and mortality of patients with multiple sclerosis in France in 2012: a study based on French health insurance data. Journal of Neurology 264:6, pages 1185-1192.
Crossref
Crossref
Juanzhi Fang, Sara Bruce Wirta & Kristijan Kahler. (2017) Secondary Use of Data: Non-Interventional Study Best Practices in Planning and Protocol Development. Journal of Health Economics and Outcomes Research 5:1, pages 27-38.
Crossref
Crossref
Tjalf Ziemssen, Jennie Medin, C. Anne-Marie Couto & Catherine R. Mitchell. (2017) Multiple sclerosis in the real world: A systematic review of fingolimod as a case study. Autoimmunity Reviews 16:4, pages 355-376.
Crossref
Crossref
Val?ry Risson, Deepanshu Saini, Ian Bonzani, Alice Huisman & Melvin Olson. (2016) Patterns of Treatment Switching in Multiple Sclerosis Therapies in US Patients Active on Social Media: Application of Social Media Content Analysis to Health Outcomes Research. Journal of Medical Internet Research 18:3, pages e62.
Crossref
Crossref